Premium
Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction
Author(s) -
Moudgil Rohit,
Hassan Saamir,
Palaskas Nicolas,
LopezMattei Juan,
Banchs Jose,
Yusuf Syed Wamique
Publication year - 2018
Publication title -
echocardiography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 62
eISSN - 1540-8175
pISSN - 0742-2822
DOI - 10.1111/echo.14012
Subject(s) - ejection fraction , medicine , cardiology , subclinical infection , cardiac function curve , heart failure , cardiac dysfunction , diastole , speckle tracking echocardiography , cardiac imaging , blood pressure
Cancer therapies have resulted in increased survivorship in oncological patients. However, the benefits have been marred by the development of premature cardiovascular disease. The current definition outlines measurement of ejection fraction as a mean to diagnose cancer therapeutic–related cardiac dysfunction ( CTRCD ); however, up to 58% of the patients do not regain their cardiac function after the CTRCD diagnosis, despite therapeutic interventions. Therefore, there has been a growing interest in the markers for early myocardial changes (ie, changes with normal left ventricular ejection fraction [ LVEF ]) that may predict the development of subsequent left ventricular ejection fraction reduction or progression to heart failure. This review will highlight the use of diastolic parameters, tissue Doppler imaging ( TDI ), and speckle tracking echocardiogram ( STE ) as emerging technologies which can potentially detect cardiac dysfunction thereby stratifying patients for cardioprotective therapies. The goal of this manuscript was to highlight the concepts and discuss the current controversies surrounding these echocardiographic imaging modalities.